An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.
about
New trends in androgen deprivation therapy: Summary of key research presented at AUA 2014In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growthTargeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.Androgen receptors beyond prostate cancer: an old marker as a new target.Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.Agonists of luteinizing hormone-releasing hormone in prostate cancer.The hurdle of antiandrogen drug resistance: drug design strategies.Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update.Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer.Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer.Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix."Neurological complications of new chemotherapy agents".Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016.Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer.Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study.
P2860
Q27009159-8D6BE104-C1C4-49ED-BDBE-D0DBD2335F43Q28545022-7732CC9A-7DCB-4929-BCA8-F8D87A59230CQ34101055-90A96DA8-F98B-4430-808D-67224F89FA44Q34458538-56B7656C-1A31-4A89-8D3B-3B44C7DC442AQ36339931-B0950AD1-E758-448C-9997-AAD01138E571Q36748502-F6002086-20E6-4C5B-93FC-3042523AA5F6Q37093547-74E82C0C-BDDD-4C1D-9C9C-B65A254F8524Q37519616-63E38FCF-D32C-489B-B6D8-E05AA45D7903Q38132229-BCE5BEB6-98B8-49E1-A24F-226E0BAD1D21Q38160927-98E788C7-D367-4213-883D-6CCA734A7F8FQ38221751-B8D406FD-2D47-43A7-989A-C1A9110AB6A8Q38323902-934B3869-8FD3-4326-8B33-5B37F4DD6B02Q39267156-C6858AF4-783F-4EEB-BE72-7733C4658F3FQ41136692-C3221B0D-045B-4CE7-8343-639ED9630671Q41868457-8356556B-19BD-472B-9BF1-059306D198AAQ42875405-B8E2CD80-E2FE-4E39-805F-D5BCE351F475Q45069581-16DF8793-C711-4B57-AF76-731419D4B113Q47153081-B0E4FA26-6C8E-4589-B3D4-FE7AEBF365FAQ54414647-EFB8F5BA-7EA8-4C57-8E93-B2DC4DE5E9DAQ55157282-1FE505CB-16EA-4EAD-A166-E56F6EB3A12B
P2860
An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
An update on the use of degare ...... one-dependent prostate cancer.
@en
type
label
An update on the use of degare ...... one-dependent prostate cancer.
@en
prefLabel
An update on the use of degare ...... one-dependent prostate cancer.
@en
P2860
P356
P1476
An update on the use of degare ...... mone-dependent prostate cancer
@en
P2093
Norman L Block
P2860
P304
P356
10.2147/OTT.S32426
P407
P577
2013-04-16T00:00:00Z